Beyza Ozturk

Selinexor enhances temozolomide efficacy in glioblastoma through modulation of multiple resistance-associated mechanisms

Introduction Glioblastoma remains one of the most treatment-resistant cancers, and temozolomide (TMZ) resistance is a central barrier to durable clinical response. Inhibition of exportin-1 (XPO1) by selinexor has emerged as a promising strategy to overcome resistance in solid tumors; however, its ability to sensitize T...